Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 3:57 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 11,377 matching trials from the live ClinicalTrials.gov search.
Conditions
GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
Interventions
PBGM01
Biological
Lead sponsor
Gemma Biotherapeutics
Industry
Eligibility
1 Month to 24 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Oakland, California • Minneapolis, Minnesota • New Brunswick, New Jersey + 1 more
Conditions
Hemophilia A
Interventions
efanesoctocog alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Peoria, Illinois
Conditions
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Urinary Bladder Neoplasms
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Morrisville, North Carolina
Conditions
Pancreatic Cancer, Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasms
Interventions
anti-EGFR-bispecific antibody armed activated T-cells
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Conditions
Acute Myocarditis
Interventions
64Cu-GRIP B is a radiolabeled peptide tracer, a copper-64 isotope bound to a peptide designed to target extracellular Granzyme B
Drug
Lead sponsor
Javid Moslehi, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Results available

COVID-19 Vaccine Response in Sickle Cell Disease

NCT05139992
Conditions
Sickle Cell Disease, COVID-19
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
ASH Research Collaborative
Other
Eligibility
Not listed
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Oakland, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more
Conditions
OME - Otitis Media With Effusion, AOM - Acute Otitis Media
Interventions
Iontophoresis & tube placement, Tube placement
Combination Product · Device
Lead sponsor
Tusker Medical
Industry
Eligibility
6 Months to 12 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Carlsbad, California • Roseville, California • San Jose, California + 14 more
Completed Not applicable Interventional Results available

Clinical Evaluation of a Cochlear Implant Sound Processor

NCT04237207
Conditions
Hearing Loss, Ear Diseases, Hearing Disorders, Otorhinolaryngologic Diseases
Interventions
Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software, 301-M062 sound processor & software
Device
Lead sponsor
Advanced Bionics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Tampa, Florida • Kansas City, Missouri + 3 more
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Cancer
Interventions
LY2801653, Cetuximab, Cisplatin, Gemcitabine, Ramucirumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • New York, New York + 2 more
Conditions
Solid Tumor
Interventions
LY3415244
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Advanced Solid Tumors
Interventions
OKI-179
Drug
Lead sponsor
OnKure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
JNJ-64264681
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy
Interventions
HFB30132A, Placebo
Drug · Other
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 1Phase 2 Interventional Results available

Sym004 in Patients With Advanced Solid Tumors

NCT01117428
Conditions
Metastatic Colorectal Cancer
Interventions
Sym004
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
suramin, paclitaxel, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD
Interventions
Satralizumab 120 mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
Interventions
18F-DCFPyL, 18F-FDG, PSMA-11
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Carcinoma
Interventions
Targeted Prostate Biopsy, Prostate Imaging Reporting & Data System, Deep Learning Artificial Intelligence, Green Learning Artificial Intelligence, Radical Prostatectomy
Procedure · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
20 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Advanced Solid Tumors
Interventions
Avelumab, M9241, Avelumab (Once weekly), M9241 (MTD), Avelumab (Expansion cohort)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
San Diego, California • Santa Rosa, California • New Haven, Connecticut + 13 more
Conditions
Healthy Participants
Interventions
CK-4021586, Placebo for CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Solid Tumor Malignancies
Interventions
Imetelstat Sodium (GRN163L)
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Detroit, Michigan